Literature DB >> 17486667

Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.

Sylvie Retout1, Emmanuelle Comets, Adeline Samson, France Mentré.   

Abstract

We extend the methodology for designs evaluation and optimization in nonlinear mixed effects models with an illustration of the decrease of human immunodeficiency virus viral load after antiretroviral treatment initiation described by a bi-exponential model. We first show the relevance of the predicted standard errors (SEs) given by the computation of the population Fisher information matrix using the R function PFIM, in comparison to those computed with the stochastic approximation expectation-maximization algorithm, implemented in the Monolix software. We then highlight the usefulness of the Fedorov-Wynn (FW) algorithm for designs optimization compared to the Simplex algorithm. From the predicted SE of PFIM, we compute the predicted power of the Wald test to detect a treatment effect as well as the number of subjects needed to achieve a given power. Using the FW algorithm, we investigate the influence of the design on the power and show that, for optimized designs with the same total number of samples, the power increases when the number of subjects increases and the number of samples per subject decreases. A simulation study is also performed with the nlme function of R to confirm this result and show the relevance of the predicted powers compared to those observed by simulation. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486667     DOI: 10.1002/sim.2910

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

1.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

2.  Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults.

Authors:  Caroline Petit; Vincent Jullien; Adeline Samson; Jérémie Guedj; Jean-René Kiechel; Sarah Zohar; Emmanuelle Comets
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

4.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

5.  Optimizing disease progression study designs for drug effect discrimination.

Authors:  Sebastian Ueckert; Stefanie Hennig; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-27       Impact factor: 2.745

6.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

7.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

8.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

9.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

10.  Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study.

Authors:  Catherine M T Sherwin; Pornswan Ngamprasertwong; Senthilkumar Sadhasivam; Alexander A Vinks
Journal:  Curr Clin Pharmacol       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.